Consortium of Early Arthritis Cohorts USA

Rheumatoid Arthritis Clinical Trial

— CATCH-US  

Official title:

Consortium of Early Arthritis Cohorts USA - A Prospective Cohort Study of Adults With New Consent Inflammatory Arthritis Symptoms to Understand Predictors of Optimal Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02386527
• Other study ID #: 2014-229
• Status: Recruiting
• Start date: December 2014
• Est. completion date: December 2023

Study information

• Verified date: August 2021
• Source: Hospital for Special Surgery, New York
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. In the US, it is estimated that as many as 3 million adults may suffer from the disease. Fortunately in the last few years, a shift in strategy toward the earlier institution of disease modifying drugs and the availability of new classes of medications have greatly improved the outcomes that can be expected by most patients.

The goal of treatment now aims toward achieving the lowest possible level of arthritis disease activity and even remission, if possible as early on as possible. Research has shown that this translates into minimized joint damage and enhanced physical function and quality of life for the RA patient. This also requires that a diagnosis of RA be made as early on as possible, and herein lies the challenge, i.e. identifying the RA patient early on in the course of their disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2400
• Est. completion date: December 2023
• Est. primary completion date: June 13, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient was 18 years of age or over at time of referral

• Joint symptoms for < 12 months

• 2+ swollen joints OR 1 swollen joint with one of the following: Rheumatoid Factor > 20 IU, (+) anti-CCP antibody, morning stiffness > 45 minutes, responded to NSAIDs, (+) MTP squeeze test

Related Conditions & MeSH terms

• Arthritis
• Rheumatoid Arthritis

Locations

Country	Name	City	State
United States	Hospital for Special Surgery	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Hospital for Special Surgery, New York

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rapidity and sustainability of SDAI remission as achieved over a one year period		3 months, 6 months, 9 months and 12 months of follow-up
Secondary	The proportion of patients achieving DAS28 remission and CDAI remission twice		3 months, 6 months, 9 months and 12 months of follow-up
Secondary	Rapid radiographic progression, as measured by a van der Heijde Sharp Score change of 5 point or more		2 months and 24 months of follow-up